Latest Nebulizer Stories

SAN DIEGO, Jan. 21 /PRNewswire/ -- Elevation Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of new aerosol therapies for patients with respiratory diseases, announced today the closing of a $30 million tranched Series A financing. Investors participating include Canaan Partners, TPG Growth, Care Capital, and Mesa Verde Venture Partners. Concurrent with this financing, Elevation has added to its board of directors Brent Ahrens, General Partner at Canaan,...

NEW YORK, Nov. 18 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Pulmonary Drug Delivery Technologies - A Global Market Perspective http://www.reportlinker.com/p0164238/Pulmonary-Drug-Delivery-Technologies---A-Global-Market-Perspective.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire Until recent years, respiratory conditions such as asthma, chronic obstructive pulmonary, and emphysema disease represented...

Anesthesia Information Management Systems Market to See a Five Fold Increase VANCOUVER, Nov. 17 /PRNewswire/ - According to a new report series by iData Research, the leading global authority in medical device, dental and pharmaceutical market research, the U.S. market for anesthesia, respiratory and sleep management devices will reach $4.1 billion by 2015. The market for sleep apnea devices, a large rapidly growing market, will represent nearly 50% of this value, while anesthesia...

MIDLOTHIAN, Va., Nov. 12 /PRNewswire/ -- Today, PARI Respiratory Equipment launched a newly updated continuing education class, Managing Respiratory Patients Through Efficient Aerosol Delivery, rounding out their free learning program with seven classes for respiratory therapists, nurses, case managers, and pharmacists. The updated class allows participants to self-study online, enabling easier access for caregivers to update their skills and receive necessary credits for maintaining...

MONMOUTH JUNCTION, N.J., Oct. 19 /PRNewswire/ -- Transave Inc., today reported additional positive clinical trial results on its lead investigational drug, ARIKACE(TM) (liposomal amikacin for inhalation), an antibiotic that aims to treat chronic lung infections. The latest results along with previously reported data demonstrate significant clinical benefits and complete the company's Phase II program in two indications - for the treatment of lung infections due to the bacterium,...

MIDLOTHIAN, Va., Oct. 1 /PRNewswire/ -- Today, PARI Respiratory Equipment introduced the PEP S, a device that provides positive expiratory pressure that can be used with all PARI LC reusable nebulizers. PARI's PEP S can be used alone or in combination with nebulizer therapies for airway clearance and lung strengthening exercises by cystic fibrosis patients. "I believe the new PARI PEP S is an incredible new device that improves patient care in two very important areas. It reduces...

MONTEREY, Calif., Sept. 23 /PRNewswire/ -- PARI Pharma's Altera, which uses eFlow Technology, is the first drug-specific nebuliser for cystic fibrosis and has been specifically developed to deliver Gilead Sciences' Cayston. Cayston, aztreonam lysine 75 mg powder and solvent for nebuliser solution, is a new antibiotic that received conditional marketing approval from the European Commission as a suppressive therapy for cystic fibrosis patients, 18 years and older, who have chronic pulmonary...

MONTEREY, Calif., Sept. 14 /PRNewswire/ -- Mpex Pharmaceuticals, Inc. reported positive top line results from a Phase 2b clinical trial with Aeroquin, a novel aerosol formulation of levofloxacin delivered by an optimized Investigational eFlow Nebulizer System from PARI Pharma. In the Mpex cystic fibrosis trial, nebulized Aeroquin met the primary endpoint of reducing bacterial counts of Pseudomonas aeruginosa in sputum after 28 days of dosing versus placebo. "It is exciting to see these...

MONMOUTH JUNCTION, N.J., Sept. 14 /PRNewswire/ -- Transave, Inc., today reported positive results from a Phase II clinical trial in non-cystic fibrosis (CF) bronchiectasis patients for its lead investigational drug, ARIKACE(TM) (liposomal amikacin for inhalation). The Phase II data indicated that ARIKACE, delivered once daily for 28 consecutive days, demonstrated superior clinical benefit compared to placebo as measured by patient and physician reported outcomes and reduction in Pseudomonas...

NAPA, Calif., Sept. 11 /PRNewswire-FirstCall/ -- Dey L.P., a subsidiary of Mylan Inc. (Nasdaq: MYL), today issued an advisory regarding the theft of two different types of its respiratory medications, Ipratropium Bromide Inhalation Solution, 0.02%, and Albuterol Sulfate Inhalation Solution, 0.083%, unit-dose vials. The lots were on a tractor-trailer that was stolen in the state of Florida. The NDC numbers for the Ipratropium product are 49502-685-31 (lot number F09089) and 49502-685-62...